Altman Advisors, Inc. Gilead Sciences, Inc. Transaction History

Altman Advisors, Inc.

$175 Million
Q2 2024

A detailed history of Altman Advisors, Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Altman Advisors, Inc. holds 20,622 shares of GILD stock, worth $1.74 Million. This represents 0.81% of its overall portfolio holdings.

Number of Shares

20,622

Previous 20,068 2.76%

Holding current value

$1.74 Million

Previous $1.47 Million 3.74%

% of portfolio

0.81%

Previous 0.72%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	BUY	$63.15 - $72.88 $34,985 - $40,375	554 Added 2.76%	20,622 $1.41 Million
Q1 2024 May 08, 2024	BUY	$71.58 - $87.29 $62,775 - $76,553	877 Added 4.57%	20,068 $1.47 Million
Q4 2023 Feb 07, 2024	SELL	$73.27 - $83.09 $9,671 - $10,967	-132 Reduced 0.68%	19,191 $1.55 Million
Q3 2023 Nov 14, 2023	BUY	$73.94 - $80.67 $13,161 - $14,359	178 Added 0.93%	19,323 $1.45 Million
Q1 2023 May 09, 2023	BUY	$77.31 - $88.08 $28,140 - $32,061	364 Added 1.94%	19,145 $1.59 Million
Q4 2022 Feb 08, 2023	SELL	$62.32 - $89.47 $41,006 - $58,871	-658 Reduced 3.38%	18,781 $1.61 Million
Q3 2022 Nov 07, 2022	BUY	$59.54 - $68.01 $1.16 Million - $1.32 Million	19,439 New	19,439 $1.2 Million
Q4 2020 Feb 10, 2021	SELL	$56.65 - $64.55 $342,959 - $390,785	-6,054 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$62.1 - $78.08 $1.54 Million - $1.93 Million	-24,723 Reduced 80.33%	6,054 $383,000
Q2 2020 Aug 12, 2020	SELL	$72.34 - $84.0 $5,425 - $6,300	-75 Reduced 0.24%	30,777 $2.37 Million
Q1 2020 Apr 20, 2020	BUY	$62.63 - $80.22 $1.93 Million - $2.47 Million	30,852 New	30,852 $2.31 Million

Others Institutions Holding GILD

# of Institutions

1,880

Shares Held

1.02B

Call Options Held

12M

Put Options Held

8.96M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $106B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Altman Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Altman Advisors, Inc. with notifications on news.

Account

Altman Advisors, Inc. Gilead Sciences, Inc. Transaction History